TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03032237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention - protein-rich
Description: Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Intervention group will receive protein-rich meals and protein-rich foods and drinks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional intervention - standard
Description: Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Control group will receive standard (not protein-rich) meals and standard foods and drinks.
Study: NCT02822612

Intervention type: DEVICE
Intervention: Binocular OCT prototype
Description: Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).

Intervention type: DEVICE
Intervention: Binocular OCT prototype
Description: Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).

Intervention type: DEVICE
Intervention: Binocular OCT prototype
Description: Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).

Intervention type: DEVICE
Intervention: Binocular OCT prototype
Description: Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
Study: NCT01068327

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Undergo radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study: NCT04893889

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Shear-wave elastography
Description: Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Shear-wave elastography
Description: Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Shear-wave elastography
Description: Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
Study: NCT03615651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention.
Study: NCT00210652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ 333369:
Description: Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
Study: NCT03839667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive diet intervention
Description: the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity intervention
Description: the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard education
Description: the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
Study: NCT02104557

Intervention type: OTHER
Intervention: Non intervention
Description: Non intervention
Study: NCT03939728

Intervention type: RADIATION
Intervention: Chest radiography and lung ultrasound
Description: We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
Study: NCT01311505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myrin© 2 (Rifampicin + Isoniazid)
Description: Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
Study: NCT02507102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voyager
Description: Non-invasive RFE therapy
Study: NCT01311505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimactane® (Rifampicin)
Description: One (1) capsule of Rifampicin 300 mg
Study: NCT00585754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: 1.5mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02960880

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY597939)
Description: 15mg, 20mg

Intervention type: DRUG
Intervention: Phenprocoumon (branded and generics)
Description: Individually adjusted dose
Study: NCT04337554

Intervention type: DEVICE
Intervention: Exoskeleton footwear
Description: Assistive footwear

Intervention type: DEVICE
Intervention: Exoskeleton footwear
Description: Assistive footwear
Study: NCT00801684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TrIP-2D
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TrIP-2SS
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TrIP-2D
Description: Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TrIP-2SS + Foradil
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Study: NCT02468843

Intervention type: DEVICE
Intervention: Biphasic DBS stimulation
Description: The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes~3. Biphasic pulse stimulation mode (immediate assessment)~4. Biphasic pulse stimulation mode (assessment at 1h)~5. Biphasic pulse stimulation mode (assessment at 2h)

Intervention type: OTHER
Intervention: Unified Dystonia Rating Scale
Description: Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.

Intervention type: OTHER
Intervention: Burke-Fahn- Marsden scale
Description: Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
Study: NCT03611634

Intervention type: OTHER
Intervention: BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE
Description: collection of saddles
Study: NCT01727531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine diphosphate
Description: 250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
Study: NCT03666598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet
Description: In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
Study: NCT03797027

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Nephrolithotomy without an abdominal cushion
Description: patients undergo prone PNCL without an abdominal cushion

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Nephrolithotomy with an 5 cm abdominal cushion
Description: patients undergo prone PNCL with an 5 cm abdominal cushion

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Nephrolithotomy with an 5 cm abdominal cushion
Description: patients undergo prone PNCL with an 10 cm abdominal cushion
Study: NCT05447988

Intervention type: DEVICE
Group type: OTHER
Intervention: Breast Tissue Expander
Description: tissue expander based breast reconstruction
Study: NCT00301873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Zometa
Description: Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
Study: NCT01764594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP7657
Description: CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT00928785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REPEVAX
Description: 1 dose of 0.5 mL at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent Tetanus vaccine
Description: 1 dose of 0.5 mL at Day 0
Study: NCT02801201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study: NCT02175472

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectramax light therapy device
Description: Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control light device
Description: The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
Study: NCT02122744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Super Rapid Magstim Stimulator
Description: The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.~The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Super Rapid Magstim Stimulator (sham)
Description: coil perpendicular to the scalp
Study: NCT02611531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Module Education (VME)
Description: Participants will complete inhaler education on a tablet device

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teach-To-Goal (TTG)
Description: Participants will complete intensive in-person inhaler education
Study: NCT01518296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic-Dantec Urodynamic System
Description: Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
Study: NCT04062643

Intervention type: DIAGNOSTIC_TEST
Intervention: Obesity assessment
Description: Body mass index (BMI (kg/m2) was calculated from measurements of weight to the nearest kg and height

Intervention type: DIAGNOSTIC_TEST
Intervention: Obesity assessment
Description: Body mass index (BMI (kg/m2) was calculated from measurements of weight to the nearest kg and height
Study: NCT00317031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate or Naltrexone
Description: mg\&d 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate or Naltrexone
Description: mg\&d 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acamprosate or Naltrexone
Description: mg\&d 90 days
Study: NCT02352207

Intervention type: OTHER
Intervention: identification of a pulmonary malformation in the fetus
Study: NCT01353794

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
Study: NCT02996604

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
Study: NCT03487913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Oral vasopressin V2 receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Oral vasopressin V2 receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Oral vasopressin V2 receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Oral vasopressin V2 receptor antagonist
Study: NCT02633475

Intervention type: GENETIC
Intervention: IL-10 polymorphism
Description: The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.

Intervention type: GENETIC
Intervention: IL-10 polymorphism
Description: The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
Study: NCT02875106

Intervention type: DEVICE
Intervention: 12-point-ECG
Description: routine recording will be 300 seconds

Intervention type: DEVICE
Intervention: 12-point-ECG
Description: routine recording will be 300 seconds

Intervention type: DEVICE
Intervention: Polar V800
Description: routine recording will be 300 seconds

Intervention type: DEVICE
Intervention: Polar V800
Description: routine recording will be 300 seconds

Intervention type: DEVICE
Intervention: 360° eMotion FAROS SET + Belt
Description: routine recording will be 300 seconds

Intervention type: DEVICE
Intervention: 360° eMotion FAROS SET + Belt
Description: routine recording will be 300 seconds

Intervention type: DEVICE
Intervention: Adidas Micoach smart run
Description: routine recording will be 300 seconds

Intervention type: DEVICE
Intervention: Adidas Micoach smart run
Description: routine recording will be 300 seconds

Intervention type: DEVICE
Intervention: TomTom Runner Cardio HRM
Description: routine recording will be 300 seconds

Intervention type: DEVICE
Intervention: TomTom Runner Cardio HRM
Description: routine recording will be 300 seconds
Study: NCT02985736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topicort Topical Spray
Study: NCT03049813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training
Description: Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.

Intervention type: OTHER
Group type: OTHER
Intervention: Supported Employment (Services as Usual)
Description: Standard supported employment services.
Study: NCT02369497

Intervention type: DEVICE
Intervention: HRA
Description: Humeral head resurfacing with the HRA device
Study: NCT03377621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: Whole Body Vibration Machine from the company Confidence Fitness
Study: NCT06572488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative SMOOTH mode Er:YAG laser
Description: Four intravaginal treatments within four months.
Study: NCT02061241

Intervention type: PROCEDURE
Intervention: Pacing in vein at site of latest mechanical activation
Description: Pacing in vein at site of latest mechanical activation

Intervention type: PROCEDURE
Intervention: Pacing in other suitable vein
Description: Pacing in other suitable vein
Study: NCT03086798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magill forceps
Description: Magill forceps techniques to facilitate nasotracheal tube advancement into trachea

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cuff inflation
Description: cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
Study: NCT04512274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Article
Description: Omeza Collagen Matrix
Study: NCT01866709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium polystyrene sulfonate
Description: Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Silicified microcrystalline cellulose
Description: Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
Study: NCT01790412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Combined two land aerobic sessions and one aquatic activities session
Study: NCT01233297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 10 mg/kg peroral for 3 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mixture
Description: Placebo mixture containing no active substance.
Study: NCT03221413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Study: NCT00627406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buserelin and Pregnyl
Description: Subcutaneous injection 0.5 mg and 1500 IU
Study: NCT02996604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
Study: NCT00627406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnyl
Description: Subcutaneous injection 5000 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buserelin and Pregnyl
Description: Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnyl
Description: Subcutaneous injection 5000 IU
Study: NCT02705131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Chiropractic Therapy
Description: patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traction Therapy
Description: patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
Study: NCT00626574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
Study: NCT03387735

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual (TAU) + Internet
Description: Patients in this group will receive TAU+internet and links to helpful websites.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + ElderTree
Description: For the patient, ElderTree provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.~For the clinic, ElderTree has a Clinician Report (CR), a visual dashboard of health-tracking data that can be customized based on the needs of the clinic. The CR provides alerts to the clinician when a patient passes a certain threshold. The dashboard is intended to help clinicians prepare for patient office visits.
Study: NCT02516917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Technique